心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JACC：一种治疗动脉粥样硬化的潜在新疗法

2018-02-06 MedSci MedSci原创

心血管动脉粥样硬化
关注

阻断CD40-CD40L的共刺激可以减少动脉粥样硬化的发生风险，但同样会造成免疫抑制。研究者前期发现了可以阻断CD40和肿瘤坏死因子受体相关因子（TRAF）6（TRAF-STOPs）的结合，却不影响CD40与TRAF2/3/5的结合，从而避免给免疫系统带来的影响。本研究的目的旨在评估TRAF-STOP疗法在动脉粥样硬化中的效果。TRAF-STOP应用在脂蛋白E敲除（Apoe-/-）小鼠上，可以减少

阻断CD40-CD40L的共刺激可以减少动脉粥样硬化的发生风险，但同样会造成免疫抑制。研究者前期发现了可以阻断CD40和肿瘤坏死因子受体相关因子（TRAF）6（TRAF-STOPs）的结合，却不影响CD40与TRAF2/3/5的结合，从而避免给免疫系统带来的影响。本研究的目的旨在评估TRAF-STOP疗法在动脉粥样硬化中的效果。TRAF-STOP应用在脂蛋白E敲除（Apoe-/-）小鼠上，可以减少单核细胞整合素和CD40的表达，从而减少动脉粥样硬化的发生。当已有动脉粥样硬化的Apoe-/-小鼠接受TRAF-STOP治疗，斑块进展停止，斑块中的胶原增多，并形成小的坏死核心，包含少量免疫细胞。这种疗法不会影响经典免疫系统的功能，包括T细胞的增殖和激活，Ig类别转换和生发中心的形成，但是会减少炎性单核细胞的CD40和整合素的表达。此外，体外实验证实TRAF-STOP方法可以减少巨噬细胞的迁移和激活。研究结果显示，TRAF-STOPs疗法可以克服长期阻断CD40分子的弊端，有望成为动脉粥样硬化的新疗法。原始出处：Tom T et al.Targeting CD40-Induced TRAF6

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1944514, encodeId=f9c21944514bc, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Aug 10 07:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853929, encodeId=af771853929f8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Apr 06 20:58:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325696, encodeId=016d132569682, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Feb 08 05:58:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554525, encodeId=cce81554525cd, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Thu Feb 08 05:58:00 CST 2018, time=2018-02-08, status=1, ipAttribution=)]
    2018-08-10 医者仁心

    #粥样硬化#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1944514, encodeId=f9c21944514bc, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Aug 10 07:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853929, encodeId=af771853929f8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Apr 06 20:58:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325696, encodeId=016d132569682, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Feb 08 05:58:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554525, encodeId=cce81554525cd, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Thu Feb 08 05:58:00 CST 2018, time=2018-02-08, status=1, ipAttribution=)]
    2018-04-06 hbwxf

    #JACC#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1944514, encodeId=f9c21944514bc, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Aug 10 07:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853929, encodeId=af771853929f8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Apr 06 20:58:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325696, encodeId=016d132569682, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Feb 08 05:58:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554525, encodeId=cce81554525cd, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Thu Feb 08 05:58:00 CST 2018, time=2018-02-08, status=1, ipAttribution=)]
    2018-02-08 12498568m50暂无昵称

    #ACC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1944514, encodeId=f9c21944514bc, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Aug 10 07:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853929, encodeId=af771853929f8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Apr 06 20:58:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325696, encodeId=016d132569682, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Feb 08 05:58:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554525, encodeId=cce81554525cd, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Thu Feb 08 05:58:00 CST 2018, time=2018-02-08, status=1, ipAttribution=)]
    2018-02-08 kcb074

    #新疗法#

    0

相关资讯

Eur Heart J：高心血管风险的糖尿病患者血压和心血管结局分析！

由此可见，对于心血管疾病风险升高的糖尿病患者，即使在对潜在疾病负担进行了广泛调整后，较低的舒张压与亚临床心肌损伤和心肌梗死风险之间仍然存在着持续的联系。

BMJ：偏头痛大幅增加主要心脑血管疾病风险

研究认为，偏头痛患者心肌梗死、缺血性卒中、出血性卒中、静脉血栓、房颤或房扑风险增加，偏头痛是重要的心脑血管疾病风险因素

Circulation：体育活动可以降低心脏事件的风险！

总所周知，较高的体力活动（PA）与较低的心力衰竭（HF）风险相关。然而，PA对HF风险的影响目前尚不清楚。近期，一项发表在杂志Circulation上的研究对11351名没有心血管疾病史的ARIC参与者（平均年龄60岁）进行了随访（1993-95）。运动PA使用改进的Baecke问卷进行评估，并根据美国心脏协会指南将其分类为推荐、中间或差。研究者们使用Cox回归模型来描述第一次（1987-1989

JACC：替卡格雷能明显改善多血管冠脉疾病患者预后

心梗（MI）和多血管冠脉疾病（MVD）患者出现反复性冠脉事件的风险大大增高。本研究的目的旨在评估替卡格雷对PEGASUS-TIMI 54临床试验中的MVD患者的有效性和安全性。有1-3年心梗病史的患者被纳入PEGASUS-TIMI 54临床试验，并根据MVD进行分层。评估替卡格雷（60mg或者90mg）对主要心血管不良事件（MACE，心源性死亡、MI和卒中）、冠脉事件（冠脉源性死亡、MI和支架内血

JACC：动脉斑块体积和形态对心肌灌注量有明显的影响

动脉粥样硬化斑块的特性可能对下游的心肌灌注和冠脉损伤的严重程度有影响。本研究的目的旨在评估斑块的数量和形态对心肌灌注和血流储备分数（FFR）的影响。本研究纳入了208例（男性占63%，平均年龄为58 ± 8.7岁）疑似有冠心病的患者。所有患者通过冠状动脉造影（CTA）对斑块的数量和形态进行评估，并通过PET和侵入性FFR诊断措施对患者心肌灌注和FFR情况进行评估。最终发现有179名患者存在动脉粥样

BMJ：小抽一根烟没事吧！对不起，你的心血管可不答应！

全世界每6个人中，就有一个人吸烟，中国烟民更多。发吸烟不仅导致肺癌等多种癌症，还会增加心血管疾病的风险。最近的一项研究显示，一根烟，也能大大提高心血管疾病发病风险。